NHS Tayside has now considered your request dated 16 January 2019.

NHS Tayside wishes to advise you that there are exemptions applicable to the information requested. Please refer to the exemptions section of this correspondence.

**Extract from Request**

“I am writing to you today to formally request the following information from your organisation.

In your trust how many patients with Multiple Sclerosis have been treated with MS disease modifying drugs in the past 6 months, latest 6 months that you can provide. Please provide the number of patients by treatment for the following disease modifying drugs.

Aubagio (teriflunomide) -
Avonex (interferon beta-1a)
Betaferon (interferon beta-1b)
Brabio (glatiramer acetate)
Cladribine (Mavenclad)
Copaxone (glatiramer acetate)
Daclizumab (Zinbryta)
Extavía (beta interferon-1b)
Gilenya (fingolimod)
Lemtrada (alemtuzumab)
Ocrevus (Ocrelizumab)
Peginterferon beta-1a (Plegridy)
Rebif (beta interferon-1a)
Tecfidera (dimethyl fumarate)
Tysabri (natalizumab)
Others
Ampyra (Fampyra)

**Response**

Where the values of statistics provided in the following data fall below 5 but are greater than 0, these statistics are represented by ‘<5’. Due to the small numbers of patients involved further detail cannot be provided as disclosure of the information may lead to the identification of individuals.

Aubagio (teriflunomide) - <5
Avonex (interferon beta-1a) - 30
Betaferon (interferon beta-1b) - <5
Brabio (glatiramer acetate) - <5
Cladribine (Mavenclad) - <5
Copaxone (glatiramer acetate) - 263
Daclizumab (Zinbryta) - 0
Extavia (beta interferon-1b) - 32
Gilenya (fingolimod) - 65
Lemtrada (alemtuzumab) - 23
Ocrevus (Ocrelizumab) - 0
Peginterferon beta-1a (Plegridy) - 14
Rebif (beta interferon-1a) - 13
Tecfidera (dimethyl fumarate) - 104
Tysabri (natalizumab) - 44
Others - <5
Ampyra (Famprima) - 0


<table>
<thead>
<tr>
<th>Document Ref.</th>
<th>FOISA Exemption Applied</th>
<th>Justification</th>
</tr>
</thead>
</table>
| IGTFOISA5815  | Section 38 (1) (a) – Personal Information | ▪ Information relating to an individual’s health care is personal information.  
▪ Disclosure of information which would allow the identification of individuals would be in breach of confidentiality and Data Protection principles. |
Freedom of Information (Scotland) Act 2002
Response to correspondence dated 16 January 2019
Request: Multiple Sclerosis Drugs
Applicant: Groups/Business
Reference: IGTFOISA 5815

Under section 20 (1) of the Act, if you are dissatisfied with the way NHS Tayside has dealt with your request, you have a right to request a review of our actions and decisions in relation to your request, and you have a right to appeal to the Scottish Information Commission.

A request for an internal review must be made in writing no later than forty working days from receipt of this response and addressed to:

Tayside NHS Board Secretary
Tayside NHS Board Headquarters
Ninewells Hospital & Medical School
Dundee
DD1 9SY

If you are not content with the outcome of the internal review, you have the right to apply directly to the Scottish Information Commissioner for a decision. The Scottish Information Commissioner can be contacted at:

Scottish Information Commissioner
Kinburn Castle
Doubledykes Road
St Andrews
Fife
KY16 9DS

Or via the online appeal service: www.itspublicknowledge.info/Appeal

If you have any queries about this correspondence, please contact:

Information Governance Team
Maryfield House
30 Mains Loan
Dundee
DD4 7BT

Telephone - 01382 424413
E-mail: informationgovernance.tayside@nhs.net

Information Governance
NHS Tayside
04 February 2019

Everyone has the best care experience possible
Headquarters: Ninewells Hospital & Medical School, Dundee, DD1 9SY (for mail) DD2 1UB (for Sat Nav)
Chairman, John Brown CBE
Chief Executive, Grant R Archibald